NCT04339426View on ClinicalTrials.gov

Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

April 20, 2020

Primary Completion Date

February 11, 2022

Study Completion Date

February 11, 2022

Conditions
Covid19
Interventions
DRUG

Atovaquone/Azithromycin

Atovaquone 750 mg PO Q12H for up to 10 Days Azithromycin 500 mg PO Daily 1 followed by 250 mg PO Daily for up to 10 days (days 2-10)

Trial Locations (1)

85258

HonorHealth, Scottsdale

Sponsors
All Listed Sponsors
lead

HonorHealth Research Institute

OTHER